Filter zurücksetzen
Stichworte
AML ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

269 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Leukemia, Myeloid, Acute NCT00875745

- 24.05.18 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT00875745

Eligibility Leukemia NCT00899171

- 19.05.18 - 1 Formular, 1 Itemgruppe, 10 Datenelemente, 1 Sprache
Itemgruppe: Criteria
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00899171

Eligibility Leukemia NCT00887068

- 18.05.18 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Randomized Allogeneic Azacitidine Study; ODM derived from: https://clinicaltrials.gov/show/NCT00887068

Eligibility Leukemia NCT00775593

- 17.05.18 - 1 Formular, 1 Itemgruppe, 23 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00775593

Eligibility Leukemia NCT00554489

- 16.05.18 - 1 Formular, 1 Itemgruppe, 15 Datenelemente, 1 Sprache
Itemgruppe: Criteria
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00554489

Eligibility Leukemia NCT00544999

- 16.05.18 - 1 Formular, 7 Itemgruppen, 22 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Inclusion Criteria, Exclusion Criteria, Inclusion Criteria, Exclusion Criteria, Inclusion Criteria, Exclusion Criteria
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00544999

GSK Study ID 104864-201-Pre-Next Course (Course 02) - Pre-Next Course

- 24.04.18 - 1 Formular, 12 Itemgruppen, 36 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Serious Adverse Experiences, 12-Lead Electrocardiogram, Echocardiogram or Multiple Gated Acquisition Scanning (MUGA), If Yes for the obtained Ejection Fraction, Chest X-Ray, Supportive Therapy (Including Erythropoietin), If Yes to Supportive Therapy (Including Erythropoietin), Supportive Anti-Infective Therapy, If Yes to Supportive Anti-Infective Therapy, Concominant Medication, If Yes to Concominant Medication
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

GSK Study ID 104864-201-Medication (next Course) - Medication

- 24.04.18 - 1 Formular, 12 Itemgruppen, 61 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Topotecan and Ara-C Study Medication Record, Topotecan Administration, Ara-C Administration, Idarubicin and Ara-C Study Medication Record, Idarubicin Administration, Ara-C Administration, Dose Reduction, Retreatment Interval, G-CSF Study Medication Record, Vital Signs-TAG Regiment only, Vital Signs-IDAG Regiment only
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

GSK Study ID 104864-201 Serious Adverse Experience - Serious Adverse Experience (SAE)

- 24.04.18 - 1 Formular, 3 Itemgruppen, 30 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Serious Adverse Experience (SAE) , Additional Informations
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

GSK Study ID 104864-201 Medication - Medication

- 24.04.18 - 1 Formular, 10 Itemgruppen, 55 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Topotecan and Ara-C Study Medication Record, Topotecan Administration, Ara-C Administration, Idarubicin and Ara-C Study Medication Record, Idarubicin Administration, Ara-C Administration, G-CSF Study Medication Record, Vital Signs-TAG Regiment only, Vital Signs-IDAG Regiment only
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

GSK Study ID 104864-201 Supportive Therapies-Transfusions, Anti-Infectives and Concominant Medication - Supportive Therapies-Transfusions, Anti-Infectives and Concominant Medication

- 24.04.18 - 1 Formular, 6 Itemgruppen, 23 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Supportive Therapy Transfusion, If Yes to Supportive Therapy (Including Erythropoietin), Supportive Anti-Infective Therapy, If Yes to Supportive Anti-Infective Therapy, Concominant Medication
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

GSK Study ID 104864-201 Adverse Experiences (non-serious) - Adverse Experiences (non-Serious)

- 24.04.18 - 1 Formular, 3 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Identification Numbers, Adverse Experiences (non-Serious), Adverse Experiences (non-Serious)
Study ID: 104864-201 Clinical Study ID: 104864/A201 Study Title: A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: topotecan Trade Name: hycamtin Study Indication: Myelodysplastic Syndrome https://www.gsk-clinicalstudyregister.com/study/104864/201?search=study&#rs

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video